225 related articles for article (PubMed ID: 20142410)
1. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis defining optimal management of clinical stage 1 high-risk nonseminomatous germ cell testicular cancer with lymphovascular invasion.
Avulova S; Allen C; Morgans A; Moses KA
Urol Oncol; 2018 Jul; 36(7):342.e1-342.e6. PubMed ID: 29754945
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.
Pont J; Albrecht W; Postner G; Sellner F; Angel K; Höltl W
J Clin Oncol; 1996 Feb; 14(2):441-8. PubMed ID: 8636755
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial.
Pont J; Höltl W; Kosak D; Machacek E; Kienzer H; Julcher H; Honetz N
J Clin Oncol; 1990 Jan; 8(1):16-20. PubMed ID: 1688613
[TBL] [Abstract][Full Text] [Related]
8. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
[TBL] [Abstract][Full Text] [Related]
9. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
10. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
11. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
Cullen M; Huddart R; Joffe J; Gardiner D; Maynard L; Hutton P; Mazhar D; Shamash J; Wheater M; White J; Goubar A; Porta N; Witts S; Lewis R; Hall E;
Eur Urol; 2020 Mar; 77(3):344-351. PubMed ID: 31901440
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of stage I nonseminomatous testicular cancer with one cycle of adjuvant chemotherapy].
Corti Ortíz D; Fonerón Burgos A; Troncoso Schifferli L
Actas Urol Esp; 1997; 21(10):961-3. PubMed ID: 9494159
[TBL] [Abstract][Full Text] [Related]
13. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
[TBL] [Abstract][Full Text] [Related]
15. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.
Tandstad T; Ståhl O; Håkansson U; Dahl O; Haugnes HS; Klepp OH; Langberg CW; Laurell A; Oldenburg J; Solberg A; Söderström K; Cavallin-Ståhl E; Stierner U; Wahlquist R; Wall N; Cohn-Cedermark G;
Ann Oncol; 2014 Nov; 25(11):2167-2172. PubMed ID: 25114021
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
17. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.
Tandstad T; Smaaland R; Solberg A; Bremnes RM; Langberg CW; Laurell A; Stierner UK; Ståhl O; Cavallin-Ståhl EK; Klepp OH; Dahl O; Cohn-Cedermark G
J Clin Oncol; 2011 Feb; 29(6):719-25. PubMed ID: 21205748
[TBL] [Abstract][Full Text] [Related]
18. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
[TBL] [Abstract][Full Text] [Related]
19. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.
Cohn-Cedermark G; Stahl O; Tandstad T;
Andrology; 2015 Jan; 3(1):102-10. PubMed ID: 25270123
[TBL] [Abstract][Full Text] [Related]
20. Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.
Tandstad T; Solberg A; Håkansson U; Stahl O; Haugnes HS; Oldenburg J; Dahl O; Kjellman A; Angelsen A; Cohn-Cedermark G;
Acta Oncol; 2015 Apr; 54(4):493-9. PubMed ID: 25192551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
